Preview Mode Links will not work in preview mode

Nov 15, 2023

Featuring perspectives from Prof Van Cutsem, including the following topics:

  • Introduction (0:00)
  • Case: A woman in her early 50s who has undergone the neoadjuvant CROSS regimen and received surgery experiences local recurrence of PD-L1-negative gastroesophageal junction (GEJ) adenocarcinoma while receiving adjuvant nivolumab — Priya Rudolph, MD, PhD (15:56)
  • Case: A man in his late 60s with localized Siewert Class III GEJ adenocarcinoma receives perioperative fluorouracil/leucovorin/oxaliplatin/docetaxel — Lai (Amber) Xu, MD, PhD (26:16)
  • Case: A woman in her early 90s who has undergone radiation therapy for esophageal squamous cell carcinoma now experiences local recurrence; PD-L1 combined positive score (CPS) is 71 — G Richard Polkinghorn, MD (36:33)
  • Case: A man in his late 60s with HER2-negative GEJ adenocarcinoma develops HER2-positive oligometastases — Matthew R Strickland, MD (42:17)
  • Case: A woman in her early 70s with metastatic HER2-positive gastroesophageal cancer who received first-line FOLFOX/trastuzumab now experiences disease progression; PD-L1 CPS is 10 — Henna Malik, MD (47:53)
  • Investigator Survey (52:26)

CME information and select publications